Marker Therapeutics, Inc.

Monthly Archives: May 2015

Phase I Study in Ovarian & Breast Cancer Published in Abstracts of 2015 ASCO Annual Meeting

…SEATTLE, Wash., May 15, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), is pleased to announce that an Abstract on a Phase I Study on the Safety and Immunogenicity of a folate receptor alpha (FRAα) peptide vaccine has been published in J Clin. Oncol., 33:5s, 2015 (suppl; abstr e14028) which, is a compilation of abstracts submitted to the 2015 ASCO Annual Meeting (http://am.asco.org/).

Read More